Current status and challenges of immunotherapy in ALK rearranged NSCLC.

Qi, Rongbin; Yu, Yingying; Shen, Mo; Lv, Dongqing; He, Susu

Qi, Rongbin; Yu, Yingying; Shen, Mo; Lv, Dongqing; He, Susu.

Afiliação

Qi R; Department of Respiratory Medicine, TaiZhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, China.
Yu Y; Department of Respiratory Medicine, TaiZhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, China.
Shen M; The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.
Lv D; Department of Respiratory Medicine, At Enze Hospital, Affiliated Taizhou Hospital of Wenzhou Medical University, Taizhou, Zhejiang, China.
He S; Department of Respiratory Medicine, TaiZhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, Zhejiang, China.

Front Oncol ; 12: 1016869, 2022.

Article em En | MEDLINE | ID: mdl-36591504

Palavras-chave

ALK; NSCLC; immune checkpoint inhibitor; immunotherapy; process

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Systematic_reviews Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google